New Fee Schedule Code (FSC) to support the transition from originator biologics to biosimilars

Biosimilar policy

The Ontario government is expanding its biologic drug coverage policy to further promote the use of biosimilars funded through the Ontario Drug Benefit (ODB) program. As a key health system partner, the Ministry of Health (“the Ministry”) is seeking support from physicians in the implementation of this policy. These changes support the Ministry’s objectives of creating a modern and sustainable drug system that continues to offer high-quality treatment, while allowing the government to fund more new drug therapies, bring innovation to the health care system and continue its work to deliver better, connected patient care.